P-201 Neoadjuvant hypofractionated intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer

Abstract

Neoadjuvant chemoradiotherapy followed by total mesorectal excision is the standard treatment in locally advanced rectal cancer (LARC) (stages II T3/T4N0 y III T N1/N2). It aims at reducing the risk of distant recurrence while pelvic radiotherapy focuses on the prevention of local recurrence. The use of advanced techniques such as Intensity-Modulated Radiotherapy (IMRT) based on multileaf collimator (MLC) allows higher doses to be delivered to the tumor volume, taking into account the tolerance dose in the organs at risk.